Matthew J Recker1,2, Cathleen C Kuo3, Dheerendra Prasad1,2,4,5, Kristopher Attwood6, Robert J Plunkett7,8. 1. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, 100 High Street, Suite B4, Buffalo, NY, 14203, USA. 2. Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 3. Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, NY, USA. 4. Department of Radiation Oncology, Jacobs School of Medicine at the University at Buffalo, Buffalo, NY, USA. 5. Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 6. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, 100 High Street, Suite B4, Buffalo, NY, 14203, USA. rplunkett@ubns.com. 8. Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. rplunkett@ubns.com.
Abstract
PURPOSE: Atypical meningiomas have histologic and clinical features that fall between those for benign and malignant meningiomas. The incidence of atypical meningiomas has not been well studied with respect to changes in the World Health Organization (WHO) classification scheme over time. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was queried to obtain data from 2004 to 2018 for patients with all meningiomas, including atypical. Age-adjusted incidence rates were generated and annual percent change (APC) in the incidence rates was calculated with joinpoint regression. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: A total of 4476 patients diagnosed with meningioma were identified from the SEER 18 registries. The incidence of atypical meningioma increased at an APC of 5.6% [95% confidence interval [CI], 3.4-7.8]; significantly faster than all meningiomas, which rose at an APC of 2.5% (95%CI 1.8-3.1;p = 0.008). For atypical meningiomas, the 1, 3, 5, and 10-year survival rates were 91.9%, 81.3%, 68.8%, and 34.3%, respectively. Male sex, older age (≥ 60 years), and large tumor size (> 5 cm) were independent risk factors for an unfavorable prognosis. CONCLUSIONS: The incidence of atypical meningioma was observed to be increasing relative to all meningiomas. It is important to diligently monitor atypical meningioma incidence and mortality rates over time to see whether observed uptrends persist. Continued effort toward improving outcomes in patients with atypical meningiomas is warranted, especially in light of an apparent rise in incidence.
PURPOSE: Atypical meningiomas have histologic and clinical features that fall between those for benign and malignant meningiomas. The incidence of atypical meningiomas has not been well studied with respect to changes in the World Health Organization (WHO) classification scheme over time. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was queried to obtain data from 2004 to 2018 for patients with all meningiomas, including atypical. Age-adjusted incidence rates were generated and annual percent change (APC) in the incidence rates was calculated with joinpoint regression. Survival was analyzed using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: A total of 4476 patients diagnosed with meningioma were identified from the SEER 18 registries. The incidence of atypical meningioma increased at an APC of 5.6% [95% confidence interval [CI], 3.4-7.8]; significantly faster than all meningiomas, which rose at an APC of 2.5% (95%CI 1.8-3.1;p = 0.008). For atypical meningiomas, the 1, 3, 5, and 10-year survival rates were 91.9%, 81.3%, 68.8%, and 34.3%, respectively. Male sex, older age (≥ 60 years), and large tumor size (> 5 cm) were independent risk factors for an unfavorable prognosis. CONCLUSIONS: The incidence of atypical meningioma was observed to be increasing relative to all meningiomas. It is important to diligently monitor atypical meningioma incidence and mortality rates over time to see whether observed uptrends persist. Continued effort toward improving outcomes in patients with atypical meningiomas is warranted, especially in light of an apparent rise in incidence.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Amir H Zamanipoor Najafabadi; Marthe C M Peeters; Linda Dirven; Daniel J Lobatto; Justus L Groen; Marieke L D Broekman; Saskia M Peerdeman; Wilo C Peul; Martin J B Taphoorn; Wouter R van Furth Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300
Authors: Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee Journal: J Neuropathol Exp Neurol Date: 2002-03 Impact factor: 3.685
Authors: David Pasquier; Stefan Bijmolt; Theo Veninga; Nicolas Rezvoy; Salvador Villa; Marco Krengli; Damien C Weber; Brigitta G Baumert; Emine Canyilmaz; Deniz Yalman; Ewa Szutowicz; Tzahala Tzuk-Shina; René O Mirimanoff Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-04 Impact factor: 7.038
Authors: Gurvinder Kaur; Eli T Sayegh; Andrew Larson; Orin Bloch; Michelle Madden; Matthew Z Sun; Igor J Barani; C David James; Andrew T Parsa Journal: Neuro Oncol Date: 2014-04-02 Impact factor: 12.300
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Amir H Zamanipoor Najafabadi; Pim B van der Meer; Florien W Boele; Martin J B Taphoorn; Martin Klein; Saskia M Peerdeman; Wouter R van Furth; Linda Dirven Journal: Neurosurgery Date: 2020-12-15 Impact factor: 4.654